iBio, Inc. announced preclinical data from an obese non-human primate study evaluating IBIO-610, an Activin E antibody candidate. The study showed a single dose of IBIO-610 reduced active Activin E levels by 98% at week 4 and 97% at week 8 compared to baseline. When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone. The company will present the full data at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan. iBio, Inc. is a biotechnology company focused on developing therapeutic antibody candidates.
